These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 16797969)

  • 1. Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy.
    Chatterjee M; Chakraborty T; Tassone P
    Eur J Cancer; 2006 Jul; 42(11):1640-52. PubMed ID: 16797969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
    Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral immunotherapy of multiple myeloma: perspectives and perplexities.
    Di Bernardo A; Macor P; Guarnotta C; Franco G; Florena AM; Tedesco F; Tripodo C
    Expert Opin Biol Ther; 2010 Jun; 10(6):863-73. PubMed ID: 20367529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elotuzumab and daratumumab: emerging new monoclonal antibodies for multiple myeloma.
    Kuroda J; Nagoshi H; Shimura Y; Taniwaki M
    Expert Rev Anticancer Ther; 2013 Sep; 13(9):1081-8. PubMed ID: 24053207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide-based immunotherapy for multiple myeloma: current approaches.
    Zhou FL; Meng S; Zhang WG; Wei YC; Cao XM; Bai GG; Wang BY
    Vaccine; 2010 Aug; 28(37):5939-46. PubMed ID: 20619381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials.
    Chiriva-Internati M; Cobos E; Kast WM
    Int Rev Immunol; 2007; 26(3-4):197-222. PubMed ID: 17558744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of novel therapeutic approaches for multiple myeloma.
    Hideshima T; Anderson KC
    Nat Rev Cancer; 2002 Dec; 2(12):927-37. PubMed ID: 12459731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal gammopathy as a model for B-cell differentiation: from "paraprotein" to artificial antibodies.
    Bast EJ; van Camp B
    Neth J Med; 1991 Oct; 39(3-4):209-15. PubMed ID: 1791883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
    Anderson KC
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple myeloma, a model for fundamental and clinical research.
    Vande Broek I; Asosingh K; Vanderkerken K; Van Riet I; Van Camp B
    Verh K Acad Geneeskd Belg; 2002; 64(4):261-84; discussion 284-6. PubMed ID: 12416235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.
    Rozemuller H; van der Spek E; Bogers-Boer LH; Zwart MC; Verweij V; Emmelot M; Groen RW; Spaapen R; Bloem AC; Lokhorst HM; Mutis T; Martens AC
    Haematologica; 2008 Jul; 93(7):1049-57. PubMed ID: 18492693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular immunotherapy for multiple myeloma.
    Rosenblatt J; Avigan D
    Best Pract Res Clin Haematol; 2008 Sep; 21(3):559-77. PubMed ID: 18790455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The development of potential antibody-based therapies for myeloma.
    Sherbenou DW; Behrens CR; Su Y; Wolf JL; Martin TG; Liu B
    Blood Rev; 2015 Mar; 29(2):81-91. PubMed ID: 25294123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.
    van de Donk NW; Kamps S; Mutis T; Lokhorst HM
    Leukemia; 2012 Feb; 26(2):199-213. PubMed ID: 21852787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-based immunotherapy in high-risk neuroblastoma.
    Johnson E; Dean SM; Sondel PM
    Expert Rev Mol Med; 2007 Dec; 9(34):1-21. PubMed ID: 18081947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production and characterization of monoclonal antibodies (MoAbs) for the ex vivo purging of the bone marrow in patients with multiple myeloma.
    Dinota A; Tazzari PL; Bontadini A; Grassi GP; Cerato C; Motta MR; Visani G; Cavo M; Gobbi M; Tura S
    J Exp Pathol; 1987; 3(4):363-7. PubMed ID: 3331648
    [No Abstract]   [Full Text] [Related]  

  • 19. Characteristics, pathogenesis, and novel treatments for multiple myeloma.
    San Miguel J
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S1-4. PubMed ID: 19791422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.
    Baxevanis CN; Perez SA; Papamichail M
    Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.